Compare LNZA & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNZA | TENX |
|---|---|---|
| Founded | 2005 | 1967 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2M | 71.1M |
| IPO Year | 2021 | 2001 |
| Metric | LNZA | TENX |
|---|---|---|
| Price | $6.32 | $1.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $14.00 | ★ $29.67 |
| AVG Volume (30 Days) | 62.4K | ★ 8.0M |
| Earning Date | 05-18-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 17.00 | N/A |
| Revenue | ★ $55,845,000.00 | N/A |
| Revenue This Year | $55.80 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.37 | ★ N/A |
| Revenue Growth | ★ 12.61 | N/A |
| 52 Week Low | $5.02 | $1.31 |
| 52 Week High | $44.00 | $19.40 |
| Indicator | LNZA | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 19.00 |
| Support Level | $5.38 | $1.31 |
| Resistance Level | $6.50 | $16.39 |
| Average True Range (ATR) | 0.42 | 0.45 |
| MACD | 0.07 | -0.59 |
| Stochastic Oscillator | 61.96 | 3.34 |
LanzaTech Global Inc is a provider of carbon management and conversion technologies, focused on transforming waste materials into high-value fuels, chemicals, and critical industrial inputs. Its mission is to drive energy resilience, industrial competitiveness, and supply chain security by leveraging scalable biotechnology solutions to maximize the value of domestic resources. The company operates in North America, Europe, the Middle East, Africa (EMEA), Asia, and Australia, with the majority of its revenue generated from North America.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.